Peptides DB
Research-centric peptide and protocol reference hub

VIP (Vasoactive Intestinal Polypeptide) record · updated 20h ago

Neuro & moodHealing & recoveryGrade A · human clinicalResearch use only
All 25 studiesJump to the evidenceCompare
What is VIP (Vasoactive Intestinal Polypeptide) used for?

Vasoactive Intestinal Peptide | Neuropeptide

How it works: VPAC receptor agonist

Primarily researched for · Neuro & mood

Development stage

where VIP (Vasoactive Intestinal Polypeptide) sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Cleared
    Phase 1
    Safety in humans
  3. 3Cleared
    Phase 2
    Efficacy signal
  4. 4Cleared
    Phase 3
    Confirmatory trials
  5. 5Current
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 91 registered trials. It describes the research record, not a recommendation.

Identity
NameVIP (Vasoactive Intestinal Polypeptide)
Chain length—
Molecular weight—
Formula—
Structure type—
ClassNeuro
Research levelModerate Research
Discovered byCurated master list · 2026
Pharmacology
MechanismVPAC receptor agonist
Route—
Half-life—
Time to peak—
Duration—
Extraction confidence0.80
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Aug 23, 2026. How this works →
Research stats
Total studies25
Human / animal / cellular5 / 11 / 3
Highest trial phasePhase 4
Years covered2024–2026
Latest study3d ago
Publication history
20242026
Research funding
446 NIH projects · $32.1M awarded · through FY2026
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

25 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
Epilepsy and premature mortality driven by inhibitory neuron dysfunction in a mouse model of <i>SCN1A</i> gain-of-function neurodevelopmental disorder
Finding100% premature mortality in 64/64 mutant mice between postnatal day 12-18.
Animal2026Full text read0.70
Non-Destructive Analysis of Phenolic and Flavonoid Contents in Medicinal Plant Powders Using Hyperspectral Imaging and Variable Selection.
FindingR² of 0.996 for flavonoid content prediction.
In vitro2026Full text read0.70
UHPLC/Q-TOF-MS-based blood-component profiling and multi-omics analysis reveal potential protective mechanisms of Shenzhuo Formula against diabetic kidney disease.
FindingReduced urinary albumin-to-creatinine ratio in db/db mice.
Animal2026Full text read0.80
Label-free plasma proteomics reveals the regulatory mechanism of Chaige Qingsan Decoction on complement and interferon pathways against influenza.
FindingC4BPB regulation confirmed by ELISA, P=0.0003.
Human2026Full text read0.80
Xiongzhi Qufeng Zhitong Granule alleviates nitroglycerin-induced migraine-like nociception and central neuroinflammation by regulating the HMGB1 / TRPV1 / MAPK signaling axis.
FindingXZQF significantly restored body weight and pain thresholds in rats.
Animal2026Full text read0.80
Mutton fat-processing enhances the anti-osteoporotic effect of Epimedium koreanum Nakai via regulating the metabolism-inflammation-bone axis.
FindingNot reported in abstract.
Animal2026Full text read0.70
ATR-FTIR spectroscopic characterization and interpretable machine learning for time since injury estimation in rat scabs.
FindingR²CV = 0.922, RMSECV = 14.456 h for Ridge regression.
Animal2026Full text read0.70
Adipokine IL-11/IL-11Ra constrains sphingolipid metabolism to limit the thermogenic capacity of beige adipocytes.
TakeawayNot reported in abstract.
—2026Title only0.10
Earliest siphuncle-bearing cephalopod from the early Cambrian.
TakeawayNot reported in abstract.
—2026Title only0.10
Risk prediction models for malnutrition in dialysis patients in China: a systematic review and meta-analysis.
Finding41% pooled prevalence of malnutrition in dialysis patients.
review2026Full text read0.80
Health education needs of stroke patients and caregivers: A qualitative meta-synthesis.
FindingNot reported in abstract.
review2026Full text read0.80
Tsamba-stir-fried Tiebangchui: Attenuates the toxicity of raw Tiebangchui without compromising its analgesic efficacy in Caenorhabditis elegans through TRPV channel regulation.
FindingNot reported in abstract.
Animal2026Full text read0.70

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching VIP (Vasoactive Intestinal Polypeptide) will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much VIP (Vasoactive Intestinal Polypeptide) is discussed should be drawn from it.